Millions of workers face a biological mismatch when their shifts begin before dawn. A recent clinical trial demonstrates that solriamfetol, a wake-promoting medication, can meaningfully improve alertness and job performance for those struggling with the sleep disorder that early schedules create.
The drug helped shift workers maintain better focus and function throughout their full work hours, according to the trial results. Those who received the medication reported improvements in alertness, productivity, and overall daily performance—gains that extend to workplace safety.
Shift work disorder affects the body's internal clock, making it difficult for workers to stay alert when their biological systems are primed for sleep. This misalignment can diminish concentration and increase accident risk, creating real consequences for workers and employers alike.
Solriamfetol works by promoting wakefulness in the brain, helping workers counteract the natural urge to sleep during early morning hours. The medication represents a potential solution for the millions of people whose jobs demand they start work before their bodies are ready.
While the trial shows promising results, solriamfetol would join a limited arsenal of treatments for shift work disorder. The medication could offer particular value for workers in industries like healthcare, transportation, and manufacturing, where early starts are common and alertness directly impacts safety and performance.
Comments